Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer, Prostate Clear all

Conditions: Prostate Cancer
Interventions: Estramustine, Etoposide, Paclitaxel; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2006
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions: abiraterone acetate, dietary intervention, pharmacological study, questionnaire administration, laboratory biomarker analysis; Drug · Dietary Supplement · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Prostate Cancer
Interventions: BN83495 (Cohort 1), BN83495 (Cohort 2), BN83495 (Cohort 3); Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Baltimore, Maryland • Durham, North Carolina • Madison, Wisconsin

Conditions: Prostate Cancer
Interventions: Radiation Therapy; Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Help with decision making on prostate cancer treatment; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 50 Years to 80 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Sedentary Lifestyle
Interventions: eHealth for Sedentary Behavior; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Urinary Urge Incontinence, Stress Urinary Incontinence, Prostatic Hyperplasia
Interventions: Elidah Device; Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Hormone-Sensitive Prostate Cancer
Interventions: PROSTVAC-V, PROSTVAC-F, Nivolumab, Ipilimumab, Neoantigen DNA vaccine, TriGrid Delivery System, Tumor biopsy, Peripheral blood, Fecal samples, Leukapheresis; Biological · Drug · Device + 1 more
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Prostate Cancer
Interventions: Radium dichloride, PET Scan; Drug · Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 7
States / cities: Aurora, Colorado • Basking Ridge, New Jersey • Middletown, New Jersey + 4 more

Conditions: Metastatic Prostate Cancer, Prostate Adenocarcinoma
Interventions: Cabozantinib, Atezolizumab, Abiraterone Acetate, Enzalutamide, Prednisone; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 575 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 36
States / cities: Tucson, Arizona • Duarte, California • Fullerton, California + 30 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: TmPSMA-02; Biological
Lead sponsor: Tceleron Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Prostate Carcinoma
Interventions: Behavioral Intervention, Biospecimen Collection, Electronic Health Record Review, Genetic Counseling, Genetic Testing, Interview, Survey Administration; Behavioral · Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Adenocarcinoma, Stage IIIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions: Hormone Therapy, Stereotactic Body Radiation Therapy; Drug · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prostate Cancer
Interventions: Relugolix; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 96
States / cities: Homewood, Alabama • Mobile, Alabama • Phoenix, Arizona + 81 more

Conditions: High-Risk Localized Prostate Cancer
Interventions: EBRT + 6 mo ADT + 177Lu-PSMA-617, EBRT + 24 mo ADT; Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cancer, Prostate Cancer
Interventions: Simvastatin, Placebo; Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years and older · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 2
States / cities: Durham, North Carolina • Portland, Oregon

Conditions: Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Androgen Receptor Pathway Inhibitor, Transdermal Estrogen, Bone Scan, Computed Tomography, Dual X-ray Absorptiometry, Gonadotropin-releasing Hormone Analog, Magnetic Resonance Imaging, Survey Administration, Biospecimen Collection; Drug · Procedure · Biological + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Metastatic Prostate Carcinoma, Metastatic Prostatic Adenocarcinoma, Prostate Carcinoma Metastatic to the Bone
Interventions: Robotic Assisted Radical Prostatectomy, Conventional open retropubic radical prostectomy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, ADT (androgen deprivation therapy) (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide); Procedure · Other · Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older · Male only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 3
States / cities: Duarte, California • Orange, California • New Brunswick, New Jersey

Conditions: Preventive Screening, Prostate Cancer, Osteoporosis, Colorectal Cancer
Interventions: Quantitative Information Sheet, Qualitative Information Sheet, Narrative Information Sheet, Framed Information Sheet; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 50 Years to 85 Years
Enrollment: 775 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Metastatic Prostate Cancer, Pain
Interventions: Radium-223; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 3
States / cities: New York, New York • Chapel Hill, North Carolina

Conditions: Prostate Cancer
Interventions: Sargramostim (GM-CSF, Leukine), Flutamide (Eulexin), PROSTVAC-F/ TRICOM, PROSTVAC-V/TRICOM; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 110 Years · Male only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 3
States / cities: Bethesda, Maryland • New Brunswick, New Jersey • Philadelphia, Pennsylvania

Conditions: Non-metastatic Prostate Cancer
Interventions: Bicalutamide, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 3,618 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2008
U.S. locations: 72
States / cities: Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 69 more

Conditions: Prostatic Neoplasms, Adenocarcinoma
Interventions: Robotic Radical Prostatectomy, Open Radical Prostatectomy; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration Resistant Prostatic Cancer, Castration Resistant Prostatic Neoplasms
Interventions: NUV-422, Enzalutamide; Drug
Lead sponsor: Nuvation Bio Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Canton, Ohio • Gettysburg, Pennsylvania • Fairfax, Virginia

Search by objective public record fields.

Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate

Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer

BN83495 in Prostate Cancer

Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer

Treatment Decision Intervention for Veterans With Prostate Cancer

Adaptation of an eHealth (Web-application) Platform for Delivery of a Sedentary Behavior Intervention Among Prostate Cancer Patients

Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer

Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy

A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX

PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT

Statin Therapy Versus Placebo Prior to Prostatectomy

Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer

Understanding and Discouraging Overuse of Potentially Harmful Screening Tests

Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer

Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer

Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer

Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy

Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC